Nicorandil Study to Reduce Cardiac Death After Percutaneous Coronary Intervention (PCI) in Hemodialysis Patients

Toujinkai Hospital129 enrolled

Overview

Survival after invasive coronary revascularization is worse in patients with chronic kidney disease than in those without it. The investigators aimed to examine whether oral administration of nicorandil, a hybrid of nitrate and adenosine triphosphate-sensitive potassium channel opener, could improve the survival of end-stage renal disease patients with coronary artery disease by inhibiting cardiac death after coronary revascularization.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

129

Conditions

Acute Myocardial Infarction Congestive Heart Failure

Interventions

NicorandilDRUG

Oral administration of nicorandil (15 mg/day)

Eligibility

Sex: ALLMin age: 30 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Hemodialysis patients with coronary artery disease who had undergone a successful first PCI with bare-metal stents between July 1, 2001 and December 31, 2003. Exclusion Criteria: * Subjects with moderate or worse cardiac valvular disease or old myocardial infarction at the point of first PCI.

Locations (1)

Toujinkai Hospital

Kyoto, Kyoto, Japan

Outcomes

Primary Outcomes

Cardiac death (sudden cardiac death, deaths due to acute myocardial infarction or congestive heart failure)

Time frame: Jan 1, 2002 to Dec 31, 2006

Secondary Outcomes

All-cause mortality

Time frame: Jan 1, 2002 to Dec 31, 2006

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.